anlon

August 13, 2026

To, **Listing Department,** **BSE Limited** **Phiroze Jeejeebhoy Towers,** **Dalal Street,** **Mumbai – 400 001** **Ref: BSE Scrip Code: 544497**	**To,** **The National Stock Exchange of India Ltd.** **The Listing Department** **Exchange Plaza,** **Bandra – Kurla Complex,** **Mumbai – 400051,** **NSE Scrip Code: AHCL**

Sub: Outcome of Board Meeting of ANLON HEALTHCARE LIMITED ("Company")

Respected Sir/Madam,

Pursuant to Regulation 30 read with Part - A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Monday, August 13, 2026, at the Registered Office of the Company *inter alia* considered and approved the following matters:

1. The Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2026 together with the reports of the Board of Directors and Auditors thereon.
2. The Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2026 together with the reports of the Board of Directors and Auditors thereon.
3. Appointment a director in place of Mr. Punitkumar Rameshbhai Rasadia (Din: 06696258) who retires by rotation and being eligible, offers himself for re-appointment. The relevant details for the same are provided in **Annexure A**.
4. Regularization of Mr. Kishan Vinodkumar Raja (DIN: 11522235) as a Non-Executive & Independent Director. The relevant details for the same are provided in **Annexure B**.
5. Appointment of Mr. Parth Sanjaybhai Udani, Proprietor of M/s. P.S. Udani & Associates, Chartered Accountant as an Internal Auditor for the financial year 2026-2027. The relevant details for the same are provided in **Annexure C**.
6. Approved remuneration of Cost Auditor of the Company.
7. Increase the authorized share capital of the Company from Rs.1,100,000,000/- (Rupees One Hundred and Ten Crore Only) to Rs.1,300,000,000 (Rupees One Hundred and Thirty Crore Only) and subsequent change in the capital clause of the Memorandum of Association of the Company subject to the approval of the shareholders of the Company at the forthcoming annual general meeting.
8. Adoption of 2 (two) share swap agreements both dated August 8, 2026, *a* entered by the Company with certain shareholders of Apiqo Organics Private Limited ("AOPL") with the intention to acquire up to 44.94% shareholding in AOPL, and certain shareholders of Bizotic Lifescience Private Limited ("BLPL") with the intention to acquire up to 47.41% shareholding in BLPL, and approval for issuance of 8,58,83,617 (Eight Crore Fifty-Eight Lakh Eighty-Three Thousand Six-Hundred Seventeen) Equity Shares of the Company on a preferential basis for consideration other than cash, to such identified shareholders of AOPL and BLPL, on an aggregate basis, in accordance

with the share exchange ratio of 1:14.45 for AOPL and 1:8.96 for BLPL, in lieu thereof, including rounding off to the nearest whole equity share for any fractional entitlement regarding of the decimal value. The specific details of these acquisitions are set out herein below:

(a) the acquisition of up to 45,16,200 (Forty-Five Lakhs Sixteen Thousand Two Hundred) equity shares i.e. 44.94% equity shareholding of AOPL by the Company for a total purchase consideration of Rs.1,165,179,600/- (Rupees One Hundred Sixteen Crore Fifty-One Lakh Seventy-Nine Thousand Six-Hundred Only) at a price of Rs.258/- (Rupees Two Hundred Fifty-Eight Only) per equity share, which shall be discharged by the Company by way of issuance and allotment of up to 6,52,76,283 (Six Crore Fifty-Two Lakhs Seventy-Six Thousand Two Hundred And Eighty-Three) fully paid up equity shares of the Company having face value of Rs.02/- (Rupee Two Only) each at a price of Rs.17.85/- (Rupees Seventeen and Eighty-Five Paise Only) per equity share (including a security premium of Rs.15.85/- (Rupees Fifteen and Eighty Five Paise Only) per share, to such identified shareholders of AOPL, including promoters and non-promoters of the Company, for consideration other than cash on a preferential basis, on such terms and conditions as may be determined by the Board in accordance with the applicable laws; and

(b) the acquisition of up to 22,99,000 (Twenty-Two Lakhs Ninety-Nine Thousand) equity shares i.e. 47.41% equity shareholding of BLPL by the Company for a total purchase consideration of Rs.367,840,000/- (Rupees Thirty-Six Crore Seventy Eight Lakhs Forty Thousand Only) at a price of Rs.160/- (Rupees One Hundred and Sixty Only) per equity share which shall be discharged by the Company by way of issuance and allotment of up to 2,06,07,334 (Two Crore Six Lakh Seven Thousand Three Hundred And Thirty-Four) fully paid-up equity shares of the Company having face value of Rs.02/- (Rupee Two Only) each at a price of Rs.17.85/- (Rupees Seventeen and Eighty-Five Paise Only) per equity share (including a security premium of Rs.15.85/- (Rupees Fifteen and Eight Five Paisa Only) per share, to such identified shareholders of BLPL, including promoters and non-promoters of the Company, for consideration other than cash on a preferential basis, on such terms and conditions as may be determined by the Board in accordance with the applicable laws.

The relevant details in relation to this item are provided in **Annexure D**, **Annexure E** and **Annexure F**.

9. Material Related Party transactions between Apiqo Organics Private Limited and the Company. The relevant details for the same are provided in **Annexure-G**.
10. Material Related Party transactions between Bizotic Lifescience Private Limited and the Company. The relevant details for the same are provided in **Annexure-H**.
11. Material Related Party transactions between Anlon Medicos Private Limited (formerly known as Remember India Health Links Private Limited) and the Company. The relevant details for the same are provided in **Annexure-I**.
12. The Board of Directors has fixed the day, date, time and place for the forthcoming Annual General Meeting ("AGM") of the Company. The Board decided that the Annual General Meeting of the Company will be held on Saturday, September 05, 2026 at 11:00 A.M. IST through through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM').
13. The Register of Members and Share Transfer Books shall remain closed from Saturday, August 29, 2026 to Friday, September 04, 2026 (both days inclusive).

14. The e-voting period commences on Wednesday, September 02, 2026 (9:00 A.M. IST) and ends on Friday, September 04, 2026 (5:00 P.M. IST).
15. During this period members of the Company holding shares either in Physical form or in dematerialized form as of Friday, August 28, 2026 (cut-off date for E-voting) may cast their vote through remote e-voting.
16. The Board has appointed M/s. K.P. Ghelani & Associates, Company Secretaries as a Scrutinizer of the Company for conducting the e-voting process in Extra –Ordinary General Meeting.

    The relevant details pursuant to Schedule III of the SEBI Listing Regulations and additional details as required under the SEBI Master Circular for compliance with the provisions of the SEBI Listing Regulations by listed entities, bearing ref. no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as annexed in **Annexure A**, **Annexure B, Annexure C**, **Annexure D**, **Annexure E, Annexure F, Annexure G, Annexure H and Annexure I**.

Meeting commenced on 05:00 p.m. IST and concluded on 07:00 p.m. IST.

You are requested to take the above information on your record.

Thanking You.
For ANLON HEALTHCARE LIMITED

MEET ATULKUMAR VACHHANI

Digitally signed by MEET ATULKUMAR VACHHANI
DN: c=IN, o=Personal, title=1318, pseudonym=fa8cdc93c1864304975a607826ec3b13, 2.5.4.20=3a6fb95c5d6b18e69b3e4b0aa280572d7c5b7c052a52b1f3df61a3beefec0029, postalCode=360005, st=Gujarat, serialNumber=1e616f51626310e14541d4d600e8532f55e8c11736b4a1df9a873673fe5caaea, cn=MEET ATULKUMAR VACHHANI
Date: 2026.08.13 20:27:47 +05'30'

PUNITKUMAR RASADIA
MANAGING DIRECTOR
DIN: 06696258

Annexure A
Details required under Regulation 30 of SEBI Listing Regulations read with HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

DIRECTOR RETIRE BY ROTATION

Details of the Directors seeking appointment and re-appointment at the Annual General Meeting of the Company: The relevant details of Directors who is proposed to be re-appointed Directors of the Company, as required under Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 and Details of the Directors seeking appointment and re-appointment at the 13th Annual General Meeting of the company:

Name of Director	Mr. Punitkumar Rameshbhai Rasadia
DIN	06696258
Nature	Re-appointment as a Chairman & Managing Director (Retire by rotation)
Date of Birth	August 19, 1985
Qualification	Master of Science in Industrial Chemistry
Date of Appointment	19/11/2013 as a Director. 15/07/2024 as a Whole Time Director.
Expertise in Specific Functional area	He has over 13 years of experience in the pharmaceutical industry, and he has a deep understanding of sourcing and supplying of specialty chemicals, intermediates, API, bulk drugs and other pharmaceutical products. His responsibilities include formulating and implementing business strategies, managing company operations, and is also responsible for growth and expansion of our business.
Directorship held in another Public Limited Company	NA
No. of Shares Held (As on 30.06.2026)	18,59,20,000
List of other Companies in which Directorship are held	ANLON LIFESCIENCE PRIVATE LIMITED CIN: U33309GJ2016PTC094751
	ADVINTEL MEDICARE PRIVATE LIMITED CIN: U33110GJ2016PTC091760
	ANLON BIOLOGICS PRIVATE LIMITED CIN: U21000GJ2026PTC180405
Chairmanship or membership on other companies	NA

Annexure B

TO REGULARIZED APPOINTMENT OF MR. KISHAN VINODKUMAR RAJA FROM ADDITIONAL NON-EXECUTIVE & INDEPENDENT DIRECTOR TO NON- EXECUTIVE & INDEPENDENT DIRECTOR

In terms of the requirements as per sub-clause (iv) of the proviso to Section II of Part II of Schedule V to the Act and pursuant to 1.2.5 of the Secretarial Standard on General Meeting (SS-2) regarding Director seeking appointment / Re-appointment information is as furnished below:

Name of the Director	Mr. Kishan Vinodkumar Raja
DIN	11522235
Nature	To Regularized Director as Appointment from Additional Non-Executive Independent Director to Non- Executive Independent Director
Date of Birth	10/11/1987
Qualification	Chartered Accountants (CA)
Date of Appointment	w.e.f. February 09, 2026
Expertise in Specific Functional area	Mr. Kishan Vinodkumar Raja is a seasoned Chartered Accountant with over 14 years of post-qualification experience, specializing in Statutory Audit, Corporate Taxation, and Corporate Finance. He is known for his meticulous approach to financial integrity and a deep understanding of the regulatory landscape governing corporate entities. The Company seeks to leverage his extensive experience in risk mitigation and financial oversight during his tenure as an Independent Director, thereby ensuring robust board-level decision-making and enhanced stakeholder protection.
Directorship held in another Public Limited Company	NIL
No. of Shares Held (As on 30.06.2026)	NO
List of other Companies in which Directorship are held	NO
Chairmanship or membership on other companies	NO

Annexure C
Details required under Regulation 30 of SEBI Listing Regulations read with HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

APPOINTMENT OF INTERNAL AUDITOR

Details with respect to appointment of Mr. Parth Sanjaybhai Udani, required under Regulation 30(6) read with Schedule III Part A Para A (7) of the Listing Regulations and SEBI Circular CIR/CFD/CMD/4/2015 dated 9 September 2015 are as follows:

Sr. No.	Disclosure requirements	Details
1.	Reason for change viz. appointment, ~~resignation~~, ~~removal~~, ~~death or otherwise~~;	Mr. Parth Sanjaybhai Udani, has appointed as an Internal Auditor of the company
2.	Date of appointment/~~cessation~~ (as applicable) & term of appointment;	With effect from August 13, 2026 **Terms of appointment:** For the financial year 2026-2027
3.	Brief profile (in case of appointment);	**Name of Internal Auditor:** Mr. Parth Sanjaybhai Udani. Mr. Parth Sanjaybhai Udani, is Proprietor of M/s. P.S. Udani & Associates, Chartered Accountants and having experience of more than 5 years in accounting, audit and financial services and accounts related services and also have knowledge about taxation.
4.	Disclosure of relationships between directors (in case of appointment of a director).	NA

Annexure D
Details required under Regulation 30 of SEBI Listing Regulations read with HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

The details relating to the issuance of fully paid-up equity shares on a Preferential Basis as required under Regulation 30 of SEBI Listing Regulations are as follows:

<table>
<tr><th>Sr. No.</th><th>Particulars</th><th>Issue of Equity Shares of the Company for consideration other than cash (Share Swap)</th></tr>
<tr><td>1</td><td>Type of securities proposed to be issued (viz. equity shares, convertibles, etc.)</td><td>Equity Shares of face value Rs.02/- (Rupees Two Only) per share.</td></tr>
<tr><td>2</td><td>Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placements, preferential allotment etc.)</td><td>Preferential Allotment for consideration other than cash (swap shares)</td></tr>
<tr><td>3</td><td>Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)</td><td>Subject to necessary approvals, up to 8,58,83,617 (Eight Crore Fifty-Eight Lakh Eighty-Three Thousand Six-Hundred Seventeen) Equity Shares shall be issued to the identified shareholders of Apiqo Organics Private Limited (“AOPL”) and Bizotic Lifescience Private Limited (“BLPL”) in accordance with the share exchange ratio of [1:14.45] (for AOPL) and [1:8.96] (for BLPL).

Any fractional entitlement arising pursuant to the swap ratio shall be rounded off to the nearest whole equity share, regardless of the decimal value.</td></tr>
<tr><td>4</td><td colspan="2">In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):</td></tr>
<tr><td>a.</td><td>Name and Number of the Investors</td><td>Name and number of investors in AOPL: Up to 160, as set out below:

<table><tr><th>Sr.</th><th>Name of Shareholders</th></tr><tr><td>1</td><td>Punitkumar Rameshbhai Rasadia</td></tr><tr><td>2</td><td>Meet Atulkumar Vachhani</td></tr><tr><td>3</td><td>Other 158 shareholders, who may accept or reject the proposal of share swap.</td></tr></table>
Name and number of investors in BLPL: Up to 173, as set out below:

<table><tr><th>Sr.</th><th>Name of Shareholders</th></tr><tr><td>1</td><td>Punitkumar Rameshbhai Rasadia</td></tr><tr><td>2</td><td>Meet Atulkumar Vachhani</td></tr></table></td></tr>
</table>

<table>
<tr><td></td><td></td><td><table><tr><td>3</td><td>Other 171 shareholders, who may accept or reject the proposal of share swap.</td></tr></table></td></tr>
<tr><td>b.</td><td>Post allotment of securities – outcome of the subscription

(in case of AOPL)</td><td>Subject to necessary approvals, the Equity Shares are proposed to be allotted to the investors of AOPL named above. Details of the shareholding in the Company, prior to and after the preferential allotment for consideration other than cash, are as under:

<table><tr><td>Name of the Shareholders</td><td>Pre-preferential Holding (No. of Share)</td><td>Post-allotment of preferential issue/ share swap Holding in AOPL (No. of Share)</td></tr><tr><td>Punitkumar Rameshbhai Rasadia</td><td>18,59,20,000</td><td>20,34,43,043</td></tr><tr><td>Meet Atulkumar Vachhani</td><td>9,40,80,000</td><td>10,25,34,740</td></tr><tr><td>Other 158 shareholders, who may accept or reject the proposal of share swap.</td><td colspan="2">Not ascertainable as these shareholders may either accept or reject the proposal of share swap.</td></tr></table>
* Details of the shareholding in the Company, prior to and after the preferential allotment for consideration other than cash, are as under assuming full acceptance of the share swap by the shareholders of AOPL and BLPL:<table><tr><td>Name of the Shareholders</td><td>Pre-preferential Holding (No. of Share)</td><td>Post-allotment of preferential issue/ share swap Holding (No. of Share)</td></tr><tr><td>Punitkumar Rameshbhai Rasadia</td><td>18,59,20,000</td><td>20,43,39,402</td></tr><tr><td>Meet Atulkumar Vachhani</td><td>9,40,80,000</td><td>10,34,31,099</td></tr></table></td></tr>
</table>

anlon

<table>
<tr><td></td><td></td><td>
<table>
<tr><td>Other 171 shareholders, who may accept or reject the proposal of share swap.</td><td>Not ascertainable as these shareholders may either accept or reject the proposal of share swap.</td></tr>
</table>
</td></tr>
<tr><td>C</td><td>Post allotment of securities – outcome of the subscription

(in case of BLPL)</td><td>Subject to necessary approvals, the Equity Shares are proposed to be allotted to the investors name above. Details of the shareholding in the Company, prior to and after the preferential issue, are as under:
<table>
<tr><td>Name of the Shareholders</td><td>Pre-preferential Holding (No. of Share)</td><td>Post-allotment of preferential issue/ share swap Holding in BLPL (No. of Share)</td></tr>
<tr><td>Punitkumar Rameshbhai Rasadia</td><td>18,59,20,000</td><td>18,68,16,359</td></tr>
<tr><td>Meet Atulkumar Vachhani</td><td>9,40,80,000</td><td>9,49,76,359</td></tr>
<tr><td>Other 171 shareholders, who may accept or reject the proposal of share swap.</td><td colspan="2">Not ascertainable as these shareholders may either accept or reject the proposal of share swap.</td></tr>
</table>
* Details of the shareholding in the Company, prior to and after the preferential allotment for consideration other than cash, are as under assuming full acceptance of the share swap by the shareholders of AOPL and BLPL:
<table>
<tr><td>Name of the Shareholders</td><td>Pre-preferential Holding (No. of Share)</td><td>Post-allotment of preferential issue/ share swap Holding (No. of Share)</td></tr>
<tr><td>Punitkumar Rameshbhai Rasadia</td><td>18,59,20,000</td><td>20,43,39,402</td></tr>
</table>
</td></tr>
</table>

		Meet Atulkumar Vachhani	9,40,80,000	10,34,31,099
		Other 171 shareholders, who may accept or reject the proposal of share swap.	Not ascertainable as these shareholders may either accept or reject the proposal of share swap.	
d.	Issue Price	Rs.17.85/- (Rupees Seventeen and Eighty-Five Paise Only) per equity share		
f.	In case of convertible intimation on the conversion of securities or on lapse of the tenure of the instrument	Not Applicable		

Annexure E

Details required under Regulation 30 of SEBI Listing Regulations read with HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sr No.	Particulars	Description
1	Name of the target entity, details in brief such as size, turnover etc.;	Name: Apiqo Organics Private Limited ("AOPL") (CIN: U21001GJ2025PTC169863) is an Indian private limited company, incorporated on December 1, 2025, by way of conversion from the partnership firm to a private limited company. Brief details: AOPL is *inter alia* engaged in manufacturing pharmaceutical intermediate, industrial and fine chemicals and inorganic chemicals, Turnover: Rs.7,254.11/- Lakh (as on 31.03.2026) and Rs.4,554.36 /- Lakh (as on 30.06.2026)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The acquisition qualifies as a Related Party Transaction under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as promoters and some of the directors are common in both entities. The promoter(s), promoter group or group companies have interest in the entity whose shareholding is proposed to be acquired. The transaction is being undertaken pursuant to the terms and conditions of the AOPL SSA executed between the parties and is on an arm's length basis.
3	Industry to which the entity being acquired belongs;	Pharmaceuticals
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The acquisition of further shares of AOPL is made with an objective to strengthen the supply of critical materials for the Company, achieve strategic synergies, and enhance long-term shareholder value.

anlon

5	Brief details of any governmental or regulatory approvals required for the acquisition;	In-principle, listing and trading approval of the stock exchanges shall be required for listing of the shares to be issued pursuant to preferential issue.
6	Indicative time period for completion of the acquisition;	The proposed acquisition is subject to completion of certain customary closing conditions under the AOPL SSA and is expected to be completed within 90 days from the date of signing of the AOPL SSA or by such other timelines as may be mutually agreed between the parties
7	Consideration - whether cash consideration or share swap or any other form and details of the same;	The transaction is proposed to be effected through a share swap agreement pursuant to which equity shares of the Company shall be issued and allotted to the shareholders of AOPL, in consideration for acquisition of their equity shares held in AOPL, subject to applicable laws and approvals. No cash consideration is expected to be payable.
8	Cost of acquisition and/or the price at which the shares are acquired;	The consideration shall be discharged by issuance of equity shares of the Company in accordance with the agreed share exchange ratio/ swap ratio. The aggregate consideration is approximately Rs.1,165,179,600/-, subject to customary adjustments, if any. <u>Cost of acquisition</u>: Rs. 1,165,179,600/- <u>Price at which shares are acquired</u>: Up to 45,16,200 equity shares at price of Rs.258/- each aggregating Rs.1,165,179,600/-.
9	Percentage of shareholding / control acquired and / or number of shares acquired;	<u>Percentage of shareholding acquired</u>: The Company expects to acquire up to 44.94% shareholding in AOPL, subject to acceptance of share swap proposal by all the shareholders of AOPL.

		Control acquired: Not applicable pursuant to the proposed transaction. Number of shares acquired: Up to 45,16,200 equity shares of the Target Company.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Brief background: Please refer (1) above. Country in which the acquired entity has presence: India Turnover for the last 3 years: Financial Year — Amt. in Lakh 2023-24 — Rs.1,711.10 2024-25 — Rs.977.78 2025-26 — Rs.7,254.11

Annexure F
Details required under Regulation 30 of SEBI Listing Regulations read with HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sr No.	Particulars	Description
1	Name of the target entity, details in brief such as size, turnover etc.;	Name: Bizotic Lifescience Private Limited ("BLPL") (CIN: U33111GJ2015PTC082917) is an Indian private limited company, incorporated on April 17, 2015. Brief details: BLPL is *inter alia* engaged in the business of manufacturing, supplying and exporting pharmaceutical drugs and intermediates, industrial and fine chemicals, more specifically, active pharmaceutical ingredients (API) including providing contract research and manufacturing services. Turnover: Rs.3,126.64/- Lakh (as on 31.03.2026) and Rs.1,152.78 /- Lakh (as on 30.06.2026)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The acquisition qualifies as a Related Party Transaction under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as promoters and some of the directors are common in both entities. The promoter(s), promoter group or group companies have interest in the entity being acquired. The transaction is being undertaken pursuant to the terms and conditions of the BLPL SSA executed between the parties and is on an arm's length basis.
3	Industry to which the entity being acquired belongs;	Pharmaceuticals
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The acquisition of further shares of BLPL is made with an objective to strengthen the operational efficiency, long-term competitiveness, achieve strategic

		synergies, and enhance long-term shareholder value.
5	Brief details of any governmental or regulatory approvals required for the acquisition;	In-principle, listing and trading approval of the stock exchanges shall be required for listing of the shares to be issued pursuant to preferential issue
6	Indicative time period for completion of the acquisition;	The proposed acquisition is subject to completion of certain customary closing conditions under the BLPL SSA and is expected to be completed within 90 days from the date of signing of the BLPL SSA or by such other timelines as may be mutually agreed between the parties.
7	Consideration - whether cash consideration or share swap or any other form and details of the same;	The acquisition is proposed to be effected through a share swap agreement, pursuant to which equity shares of the Company shall be allotted to the shareholders of BLPL, in consideration for acquisition of their equity shares held in BLPL, subject to applicable laws and approvals. No cash consideration is expected to be payable.
8	Cost of acquisition and/or the price at which the shares are acquired;	The consideration shall be discharged by issuance of equity shares of the Company in accordance with the agreed share exchange ratio/ swap ratio. The aggregate consideration is approximately Rs.367,840,000/-, subject to customary adjustments, if any. <u>Cost of acquisition</u>: Rs.367,840,000/- <u>Price at which shares are acquired</u>: Up to 22,99,000 equity shares at price of Rs.160/- each aggregating Rs.367,840,000/-.
9	Percentage of shareholding / control acquired and / or number of shares acquired;	<u>Percentage of shareholding acquired</u>: The Company expects to acquire up to 47.41% shareholding

		in BLPL, subject to acceptance of share swap proposal by all the shareholders of BLPL. Control acquired: Not applicable pursuant to the proposed transaction. Number of shares acquired: Up to 22,99,000 equity shares of the Target Company
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Brief background: Please refer (1) above. Country in which the acquired entity has presence: India Turnover for the last 3 years: Financial Year / Amt. in Lakh 2023-24 / Rs.380.39 2024-25 / Rs.3,038.20 2025-26 / Rs.3,126.64

anlon

ANNEXURE G
Details required under Regulation 30 of SEBI Listing Regulations read with HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sr. No.	Description	Details
	A. Details of the related party and transactions with the related party	
1	Name of the Related Party (A1)(1)	Apiqo Organics Private Limited
2	Country of Incorporation of the Related Party (A1)(2)	India
3	Nature of Business of the Related Party (A1)(3)	Pharmaceuticals
	A (2) Relationship and ownership of the related party	
1	Relationship between the Company and the related party – including nature of its concern (financial or otherwise) and the following (A2)(1)	Apiqo Organics Private Limited is a subsidiary of Anlon Healthcare Limited ("AHL"), which is a related party of Apiqo Organics Private Limited ("AOPL"), an unlisted subsidiary of the Company. In addition, Mr. Meet Atulkumar Vachhani (DIN: 06695053) Whole time Director of the company also holds the position of Executive Director at AOPL.
	➢ Shareholding of the Company, whether direct or indirect, in the related party.	The AHL holds 55.06% shareholding in AOPL
	➢ Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the Company.	Not applicable
	➢ Shareholding of the related party, whether direct or indirect, in the Company.	Direct
	A (3) Details of previous transactions with the related party	

1	Total amount of all the transactions undertaken by the Company or subsidiary with the related party during the last financial year (A3)(1)	Nature of Transaction: Purchase and sale of goods, rendering and receiving of services — Amount (Rs. In Lakhs) FY 2025-2026: 1 ,994.14 Nature of Transaction: Investments in Securities — Amount (Rs. In Lakhs) FY 2025-2026: 526.20
2	Total amount of all the transactions undertaken by the Company or subsidiary with the related party during the current financial year up to the quarter immediately preceding the quarter in which approval was sought (A3)(2)	Not applicable
3	Default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the Company or its subsidiary during the last financial year. (A3)(3)	Not applicable
A (4) Amount of the proposed transactions (All Types of Transactions taken together)		
1	Total Amount of all the proposed transactions being placed for approval in the meeting of the Audit Committee/ shareholders. (A4)(1)	Rs.20000 Lakh
2	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT? (A4)(2)	Yes
3	Value of the proposed transactions as a percentage of the Company's annual consolidated turnover for the immediately preceding financial year (A4)(3)	116.31%
4	Value of the proposed transactions as a percentage of subsidiary's annual consolidated turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary and where the listed entity is not a party to the transaction) (A4)(4)	Not applicable

5	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year (A4)(5)	603.56%
6	Consolidated Financial performance of the related party for the immediately preceding financial year (A4)(6) The above information is to be given on standalone basis. If standalone is not available, provide on consolidated basis	<table><tr><td>Particulars</td><td>Year ended 31/03/2026</td></tr><tr><td>Turnover</td><td>Rs. 2842.68 Lakhs</td></tr><tr><td>Profit/Loss after Tax</td><td>Rs. 86.96 Lakhs</td></tr><tr><td>Net Worth</td><td>Rs. 4,333.31 Lakhs</td></tr></table>
	A (5) Basic details of the proposed transaction	
1	Specific type of the proposed transaction (A5)(1)	01. Sales, Purchases and Jobwork 02. Acquisition of equity shares
2	Details of each type of the proposed Transaction (A5)(2)	01. At arms' length or at fair market value (Based on quotations) 02. As per Valuation Report
3	Tenure of the proposed transaction (tenure in number of years or months to be specified) (A5) (3)	01. up to the date of next AGM 02. The proposed acquisition is expected to be completed within 90 days from the date of signing of the AOPL SSA or by such other timelines as may be mutually agreed between the parties
4	Whether omnibus approval is being sought? (A5)(4)	No
5	Value of the proposed transaction during a financial year. (If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise) (A5)(5)	01. Rs.12000 Lakh – Acquisition of Share 02. Rs.8000 Lakh – Purchase and Sales
6	Justification as to why the RPTs proposed to be entered into are in the interest of the Company. (A5)(6)	The proposed acquisition is being undertaken on an arm's length basis and is considered commercially beneficial to the Company. The transaction will strengthen the Company's manufacturing capacity, support its long-term growth plans, and is in the best interest of the Company and its shareholders.

ANLON HEALTHCARE LIMITED
CIN No.: L24230GJ2013PLC077543
REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)
PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in

anlon

7	Details of the promoter(s)/ director(s) / key managerial personnel of the Company who have interest in the transaction, whether directly or indirectly. (A5)(7)	01. Mr. Punitkumar Rasadia and 02. Mr. Meet Atulkumar Vachhani, the promoter(s)/Director(s)/Key Managerial Personnel of the Company are interested in the proposed transaction.
8	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee. (A5)(8)	The valuation report was placed before the Audit Committee
9	Other information relevant for decision making. (A5)(9)	All relevant / important information forms part of this Statement setting out material facts pursuant to Section 102(1) of the Act.
B (1) Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transactions and trade advances		
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.(B1) (1)	Not applicable
2	Basis of determination of price(B1)(2)	Arm's Length Basis
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following: a. Amount of trade advance; b. Tenure; c. Whether same is self-liquidating?(B1)(3)	As Per General Pricing Terms
Specific Disclosure in case of transaction relating to investments		
1	Source of funds in connection with the proposed transaction (B3)(1)	Not Applicable as the company is acquired shares through swapping of shares.
2	Whether any financial indebtedness is incurred to make investment, specify the following: a. Nature of indebtedness b. Total cost of borrowing c. Tenure d. Other details (B3)(2)	Not applicable
3	Purpose for which funds shall be utilized by the investee company (B3)(3)	Not applicable
4	Material terms of the proposed transaction (B3)(4)	Acquisition of 45,16,200 equity shares of Apiqo Organics Private Limited (“AOPL” or "Target Company")

Disclosure only in case of transactions relating to any investment made by the listed entity or its subsidiary		
1	Latest credit rating of the related party(C2)(1)	Not applicable
2	Whether any regulatory approval is required. If yes, whether the same has been obtained. (C2)(2)	Not applicable

Annexure H

Details required under Regulation 30 of SEBI Listing Regulations read with HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sr. No.	Description	Details
Basic Details of the Material RPTs		
1	Name of the Related Party (A1)(1)	Bizotic Life Science Private Limited
2	Country of Incorporation of the Related Party (A1)(2)	India
3	Nature of Business of the Related Party (A1)(3)	Pharmaceuticals
A (2) Relationship and ownership of the related party		
4	Relationship between the Company and the related party – including nature of its concern (financial or otherwise) and the following (A2)(1)	Bizotic Life Science Private Limited is a subsidiary of Anlon Healthcare Limited ("AHL"), which is a related party of Bizotic Life Science Private Limited ("BLPL"), an unlisted subsidiary of the Company. In addition, Mr. Meet Atulkumar Vachhani (DIN: 06695053) Whole time Director also holds the position of Executive Director at BLPL.
	➢ Shareholding of the Company, whether direct or indirect, in the related party.	The AHL holds 52.59% shareholding in BLPL
	➢ Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the Company.	Not applicable
	➢ Shareholding of the related party, whether direct or indirect, in the Company.	Direct
A (2) Relationship and ownership of the related party		
1	Total amount of all the transactions undertaken by the Company or subsidiary with the related party during the last financial year (A3)(1)	Nature of Transaction: Amount (Rs. In Lakhs) FY 2025-2026 Purchase and sale of goods: 640.00 Investments in Securities: 388.78

ANLON HEALTHCARE LIMITED
CIN No.: L24230GJ2013PLC077543
REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)
PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in

2	Total amount of all the transactions undertaken by the Company or subsidiary with the related party during the current financial year up to the quarter immediately preceding the quarter in which approval was sought (A3)(2)	Rs.56.34 Lakhs
3	Default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the Company or its subsidiary during the last financial year. (A3)(3)	Not applicable
A (4) Amount of the proposed transactions (All Types of Transactions taken together)		
1	Amount of the proposed transactions placed for approval in the meeting of the Audit Committee/ shareholders. (A4)(1)	Rs.10,000 Lakhs
1	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT? (A4)(2)	Yes
3	Value of the proposed transactions as a percentage of the Company's annual consolidated turnover for the immediately preceding financial year (A4)(3)	58.15%
4	Value of the proposed transactions as a percentage of subsidiary's annual consolidated turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary and where the listed entity is not a party to the transaction) (A4)(4)	Not applicable
5	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year (A4)(5)	319.90%

6	Consolidated Financial performance of the related party for the immediately preceding financial year (A4)(6) The above information is to be given on standalone basis. If standalone is not available, provide on consolidated basis	<table><tr><td>Particulars</td><td>Year ended 31/03/2026</td></tr><tr><td>Turnover</td><td>Rs. 3126.64 Lakhs</td></tr><tr><td>Profit/Loss after Tax</td><td>Rs. (6.32) Lakhs</td></tr><tr><td>Net Worth</td><td>Rs. 1083.82 Lakhs</td></tr></table>
	A (5) Basic details of the proposed transaction	
1	Specific type and details of the proposed transaction (A5)(1) & (2)	01. Sales, Purchases and Jobwork 02. Acquisition of equity shares
2	Details of each type of the proposed Transaction (A5)(2)	01. At arms' length or at fair market value (Based on quotations) 02. As per Valuation Report
3	Tenure of the proposed transaction (tenure in number of years or months to be specified) (A5) (3)	01. up to the date of next AGM 02. The proposed acquisition is expected to be completed within 90 days from the date of signing of the AOPL SSA or by such other timelines as may be mutually agreed between the parties
4	Whether omnibus approval is being sought? (A5)(4)	No
5	Value of the proposed transaction during a financial year. (If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise) (A5)(5)	01. Rs.4000 Lakh – Acquisition of Shares 02. Rs.6000 Lakh –Purchase and Sales
6	Justification as to why the RPTs proposed to be entered into are in the interest of the Company. (A5)(6)	The proposed acquisition is being undertaken on an arm's length basis and is considered commercially beneficial to the Company. The transaction will strengthen the Company's manufacturing capacity, support its long-term growth plans, and is in the best interest of the Company and its shareholders.
7	Details of the promoter(s)/ director(s) / key managerial personnel of the Company who have interest in the transaction, whether directly or indirectly. (A5)(7)	01. Mr. Punitkumar Rasadia and 02. Mr. Meet Atulkumar Vachhani, the promoter(s)/Director(s)/Key Managerial Personnel of the Company are interested in the proposed transaction.

8	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee. (A5)(8)	The valuation report was placed before the Audit Committee
9	Other information relevant for decision making. (A5)(9)	All relevant / important information forms part of this Statement setting out material facts pursuant to Section 102(1) of the Act.
Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transactions and trade advances		
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.(B1) (1)	Not applicable
2	Basis of determination of price(B1)(2)	Arm's Length Basis
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice) , if any, proposed to be extended to the related party in relation to the transaction, specify the following: a. Amount of trade advance; b. Tenure; c.Whether same is self-liquidating?(B1)(3)	As Per General Pricing Terms
Specific Disclosure in case of transaction relating to investments		
1	Source of funds in connection with the proposed transaction (B3)(1)	Not Applicable as the company is acquired shares through swapping of shares.
2	Whether any financial indebtedness is incurred to make investment, specify the following: e. Nature of indebtedness f. Total cost of borrowing g. Tenure h. Other details (B3)(2)	Not applicable
3	Purpose for which funds shall be utilized by the investee company (B3)(3)	Not applicable
3	Material terms of the proposed transaction (B3)(4)	Acquisition of 22,99,000 equity shares of Bizotic Lifescience Private Limited ("BLPL" or "Target Company")
Disclosure only in case of transactions relating to any investment made by the listed entity or its subsidiary		

1	Latest credit rating of the related party(C2)(1)	Not applicable
2	Whether any regulatory approval is required. If yes, whether the same has been obtained. (C2)(2)	Not applicable

Annexure I
Details required under Regulation 30 of SEBI Listing Regulations read with HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sr. No.	Description	Details
Basic Details of the Material RPTs		
1	Name of the Related Party (A1)(1)	Anlon Medicos Private Limited (Formerly Known as Remember India Health Links Private Limited)
2	Country of Incorporation of the Related Party (A1)(2)	India
3	Nature of Business of the Related Party (A1)(3)	Pharmaceuticals
A (2) Relationship and ownership of the related party		
1	Relationship between the Company and the related party – including nature of its concern (financial or otherwise) and the following (A2)(1)	Anlon Medicos Private Limited is a subsidiary of Anlon Healthcare Limited ("AHL"), which is a related party of Anlon Medicos Private Limited ("AMPL"), an unlisted subsidiary of the Company. In addition, Mr. Meet Atulkumar Vachhani (DIN: 06695053), Whole time Director also holds the position of Managing Director at AMPL.
	➢ Shareholding of the Company, whether direct or indirect, in the related party.	The AHL holds 56.83 % shareholding in AMPL
	➢ Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the Company.	Not applicable
	➢ Shareholding of the related party, whether direct or indirect, in the Company.	Direct
A (3) Details of previous transactions with the related party		
1	Total amount of all the transactions undertaken by the Company or subsidiary with the related party during the last financial year (A3)(1)	Not Applicable

2	Total amount of all the transactions undertaken by the Company or subsidiary with the related party during the current financial year up to the quarter immediately preceding the quarter in which approval was sought (A3)(2)	Not Applicable
3	Default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the Company or its subsidiary during the last financial year. (A3)(3)	Not applicable
A (4) Amount of the proposed transactions (All Types of Transactions taken together)		
1	Amount of the proposed transactions placed for approval in the meeting of the Audit Committee/ shareholders. (A4)(1)	Rs.5000 Lakhs
2	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT? (A4)(2)	Yes
3	Value of the proposed transactions as a percentage of the Company's annual consolidated turnover for the immediately preceding financial year (A4)(3)	28.33%
4	Value of the proposed transactions as a percentage of subsidiary's annual consolidated turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary and where the listed entity is not a party to the transaction) (A4)(4)	Not applicable
5	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year (A4)(5)	Not applicable

6	Consolidated Financial performance of the related party for the immediately preceding financial year (A4)(6) The above information is to be given on standalone basis. If standalone is not available, provide on consolidated basis	<table><tr><td>Particulars</td><td>Year ended 31/03/2026</td></tr><tr><td>Turnover</td><td>Rs. 10.65 Lakhs</td></tr><tr><td>Profit/Loss after Tax</td><td>Rs. (489.60) Lakhs</td></tr><tr><td>Net Worth</td><td>Rs. (433.61) Lakhs</td></tr></table>
A (5) Basic details of the proposed transaction		
1	Specific type and details of the proposed transaction (A5)(1) & (2)	Sales and Purchases
2	Details of each type of the proposed Transaction (A5)(2)	At arms' length or At fair market value (Based on quotations)
3	Tenure of the proposed transaction (tenure in number of years or months to be specified) (A5) (3)	01. up to the date of next AGM
4	Whether omnibus approval is being sought? (A5)(4)	No
5	Value of the proposed transaction during a financial year. (If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise) (A5)(5)	Rs.5000 Lakhs
6	Justification as to why the RPTs proposed to be entered into are in the interest of the Company. (A5)(6)	The proposed acquisition is being undertaken on an arm's length basis and is considered commercially beneficial to the Company. The transaction will strengthen the Company's manufacturing capacity, support its long-term growth plans, and is in the best interest of the Company and its shareholders.
7	Details of the promoter(s)/ director(s) / key managerial personnel of the Company who have interest in the transaction, whether directly or indirectly. (A5)(7)	01. Mr. Punitkumar Rasadia and 02. Mr. Meet Atulkumar Vachhani, the promoter(s)/Director(s)/Key Managerial Personnel of the Company are interested in the proposed transaction.
8	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee. (A5)(8)	Not Applicable
9	Other information relevant for decision making. (A5)(9)	All relevant / important information forms part of this Statement setting out material facts pursuant to Section 102(1) of the Act.

Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transactions and trade advances		
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.(B1) (1)	Not applicable
2	Basis of determination of price(B1)(2)	Arm's Length Basis
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice) , if any, proposed to be extended to the related party in relation to the transaction, specify the following: a. Amount of trade advance; b. Tenure; c.Whether same is self-liquidating?(B1)(3)	As Per General Pricing Terms
Specific Disclosure in case of transaction relating to investments		
1	Source of funds in connection with the proposed transaction (B3)(1)	Not Applicable
2	Whether any financial indebtedness is incurred to make investment, specify the following: i. Nature of indebtedness j. Total cost of borrowing k. Tenure l. Other details (B3)(2)	Not applicable
3	Purpose for which funds shall be utilized by the investee company (B3)(3)	Not applicable
3	Material terms of the proposed transaction (B3)(4)	Not Applicable
Disclosure only in case of transactions relating to any investment made by the listed entity or its subsidiary		
1	Latest credit rating of the related party(C2)(1)	Not applicable
2	Whether any regulatory approval is required. If yes, whether the same has been obtained. (C2)(2)	Not applicable